2850-36-4Relevant articles and documents
Preparation of nucleoside uronamides as A3 adenosine receptor agonists.
-
, (2008/06/13)
The present invention provides N 6-benzyladenosine-5'-N-uronamide and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A 3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A 3 adenosine receptor a therapeutically effective amount of a compound which binds with the A. sub.3 receptor so as to stimulate an A 3 receptor-dependent response.
Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A3 Adenosine Receptors
Kim, Hea Ok,Ji, Xiao-duo,Melman, Neli,Olah, Mark E.,Stiles, Gary L.,Jacobson, Kenneth A.
, p. 3373 - 3382 (2007/10/02)
1,3-Dialkylxanthine analogues containing carboxylic acid and other charged groups on 8-position substituents were synthesized.These derivatives were examined for affinity in radioligand binding assays at rat brain A3 adenosine receptors stably